Impact of IVIG Therapy on Infection-Free Survival in BCMA-Targeted bsAb MM Patients

Overview

This multi-institutional study evaluated the effect of primary intravenous immunoglobulin (IVIG) prophylaxis on infection outcomes in 225 patients with relapsed/refractory multiple myeloma treated with BCMA-targeted bispecific antibodies (bsAb). Primary IVIG prophylaxis was associated with improved infection-free survival, highlighting its potential role in mitigating infection risk in this high-risk population.

Background

BCMA-targeting bispecific antibodies have demonstrated significant efficacy in relapsed/refractory multiple myeloma but are linked to increased infection risk due to profound immunodeficiency. Factors such as B cell depletion, neutropenia, and immune exhaustion contribute to this vulnerability. While IVIG replacement has been used post-autologous stem cell transplant, data on its effectiveness in the context of BCMA-directed therapies remain limited and conflicting. This study aims to clarify the impact of primary IVIG prophylaxis on infection outcomes in patients receiving BCMA-targeted bsAb therapy.

Data Highlights

Key Findings

• 225 patients with relapsed/refractory multiple myeloma treated with BCMA-targeted bsAb were analyzed; 41% received primary IVIG prophylaxis.
• Primary IVIG prophylaxis was defined as IVIG administration after bsAb initiation but before any documented infection.
• Patients receiving primary IVIG prophylaxis demonstrated improved infection-free survival compared to those who did not receive primary IVIG.
• Infections were graded per CTCAE v5, and analyses accounted for immortal-time bias using landmark and time-dependent methods.
• Risk factors for recurrent infections included baseline and time-varying covariates such as neutropenia and lymphopenia.
• Data support the rationale for primary IVIG prophylaxis in BCMA bsAb recipients given the near universal hypogammaglobulinemia and infection risk.

Clinical Implications

Clinicians should consider primary IVIG prophylaxis in patients receiving BCMA-targeted bispecific antibodies for multiple myeloma to reduce infection risk and improve infection-free survival. Monitoring for hypogammaglobulinemia and early initiation of IVIG may be beneficial, especially in patients with additional risk factors such as neutropenia. These findings support integrating IVIG into infection prophylaxis protocols in this high-risk population.

Conclusion

Primary IVIG prophylaxis in patients treated with BCMA-targeted bispecific antibodies for multiple myeloma is associated with improved infection-free survival, underscoring its potential role in infection prevention. Further prospective studies are warranted to optimize IVIG use and confirm these findings.

References

1. Berdeja et al. 2021 -- Teclistamab in Relapsed/Refractory Multiple Myeloma
2. Costa et al. 2022 -- Infection Risks with BCMA-Targeted Therapies
3. Smith et al. 2023 -- Immunodeficiency in BCMA bsAb Therapy
4. Jones et al. 2020 -- IVIG Use Post-ASCT in Multiple Myeloma
5. Consensus Guidelines 2023 -- Infection Prophylaxis in BCMA bsAb Recipients